The gene editing and gene modulation technology company’s portfolio now includes first-to-market CRISPRi (interference) and CRISPRa (activation) screening services.
Dr. Ben Cross, team leader, discovery screening at Horizon told us the new service capitalizes on the company’s existing platform.
“The new services provide novel tools with which customers can explore gene function through high-throughput screening. This provides the opportunity to discover and validate novel targets and to uncover novel biological phenomena,” he explained.
The services include whole-genome CRISPRi and CRISPRa functional genomic screening, which Cross said provides customers “the chance to ask how every gene in the human genome affects and influences the biological pathway that they are studying.”
According to Horizon, CRISPRi screening is more apt to study essential genes and genes amplified in the genome and CRISPRa screening enables gene activation-linked response study on a genome-wide level.